| Similar Articles |
|---|
 |
Chemistry World
April 1, 2015
Sanjay Kumar |
Sun Pharma snares Ranbaxy in $4bn deal Sun Pharma is now the fifth largest generics drug company in the world.   |
Chemistry World
April 9, 2014
Andy Extance |
Sun set on Ranbaxy rescue India's Sun Pharma will acquire its compatriot Ranbaxy in a $3.2 billion all-share deal that will create the world's fourth largest generic drugs producer. |
Chemistry World
June 13, 2008
Sarah Houlton |
Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses. |
Chemistry World
May 7, 2014
Phillip Broadwith |
Insider trading allegations stall Sun -- Ranbaxy deal The merger deal that would create India's largest pharmaceutical company has been stalled by accusations of insider trading of shares in the lead-up to the takeover announcement. |
Chemistry World
July 28, 2008
Rebecca Trager |
Ranbaxy troubles place FDA under fire Indian drug firm Ranbaxy is facing scrutiny by American federal agencies and lawmakers over allegations that the company falsified scientific evidence to gain US approval for its products. |
Chemistry World
May 23, 2013
Phillip Broadwith |
$500m fine over generics fraud for Ranbaxy A long-running investigation by the US Department of Justice and Food and Drug Administration has ended with a $500 million fine for generic drugmaker Ranbaxy. |
Chemistry World
May 3, 2012
Akshat Rathi |
Ranbaxy launches new anti-malarial Synriam It is the first recently developed antimalarial that is not based on artemisinin, one of the most effective treatments for malaria, which has begun to suffer from problems with resistance in recent years. |
The Motley Fool
July 22, 2008
Brian Orelli |
The Growth Doctor Is In Dr. Reddy's grows the top line, but it still has some work to do. |
The Motley Fool
September 18, 2008
Brian Orelli |
Ranbaxy's Troubles Won't Help Competitors The FDA will block the importing of more than 30 drugs and ingredients until Ranbaxy's problems at two Indian manufacturing plants are resolved. |
Chemistry World
October 28, 2015
Phillip Broadwith |
Job cuts at Daiichi, Perrigo and Cabot Three pharma firms -- Daiichi Sankyo, Perrigo and Allergan -- and specialty chemicals company Cabot are to cut thousands of jobs between them in restructuring efforts. |
BusinessWeek
February 27, 2006
Einhorn & Kripalani |
In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals. |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
BusinessWeek
July 14, 2003
Einhorn & Kripalani |
In India a Little Lab Work and Lots of Lawyers Ranbaxy, a maker of generic drugs, must win lawsuits to grow |
The Motley Fool
January 14, 2005
Ben McClure |
Is Buying Sun a Bright Idea? Whether you love or hate Sun Microsystems depends on your investment style. |
Chemistry World
November 21, 2014
Rebecca Trager |
Ranbaxy sues over withdrawn US approvals Ranbaxy -- India's largest generics manufacturer -- has sued the US Food and Drug Administration after the agency withdrew tentative approval for the company to sell generic versions of two blockbuster drugs |
BusinessWeek
October 17, 2005
Kripalani & Rowley |
Japan's Indian Love Affair Japanese investors are pouring billions into Indian stocks, but are they too late? |
The Motley Fool
February 22, 2005
Rich Duprey |
Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%. |
The Motley Fool
January 26, 2006
Steven Mallas |
Sun: Avert Your Portfolio's Eyes Buy Sun Microsystems? The former tech star has seen its stock struggle for a long time now, and its most recent quarterly results won't help much. |
InternetNews
July 22, 2010 |
Oracle Looks to Calm Sun Customer Concerns A Garter report found that Sun customers aren't happy with the flow of information from the company's new owner. Now Oracle is moving to calm frustrated Sun users. |
InternetNews
January 24, 2008
Andy Patrizio |
Sun Tops Estimates in Second Quarter Total sales for Sun Microsystems came in slightly higher than expected and profits almost doubled from the year-ago quarter. |
Chemistry World
August 21, 2015
Sa njay Kumar |
Indian pharma under increased regulatory scrutiny A Europe-wide ban on hundreds of generic pharmaceutical formulations tested by Indian contract research firm GVK Biosciences comes into force today. |
InternetNews
April 3, 2009
Sean Michael Kerner |
IBM-Sun Acquisition to Be Announced Today? Talk about a potential acquisition of Sun by IBM has been swirling for the last few weeks and now has hit a new level. |
Chemistry World
February 16, 2015
Phillip Broadwith |
Teva wins generic esomeprazole race The copycat version will be marketed by Ivax Pharmaceuticals, a subsidiary of Israeli generic behemoth Teva. |
Pharmaceutical Executive
September 1, 2008
Sarah Houlton |
Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units. |
InternetNews
August 30, 2007
Andy Patrizio |
Sun Hits The BRICs Emerging markets are the place to be, says Sun's CEO. |
The Motley Fool
May 2, 2008
Anders Bylund |
Sun's Cloudy Vision Sun Microsystems publishes a train wreck of a quarterly report. |
The Motley Fool
June 29, 2005
Tom Taulli |
Seeing Beyond Sun In light of the deflation in hardware prices, Sun has recently begun shifting its business toward software. Unfortunately, as usual, Sun is playing catch-up. In the tech world, that's usually a loser's strategy. Investors, take note. |
The Motley Fool
July 28, 2005
Tom Taulli |
Is Sun Getting Eclipsed? Maybe the best strategy for Sun is just to give money back to its shareholders. |
BusinessWeek
April 18, 2005
Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. |
InternetNews
February 2, 2005
Michael Singer |
Sun Expands Services With 'Infinite Bench' The company creates an 'Infinite Bench' to sit somewhere between IBM Global Services and Microsoft. |
InternetNews
January 12, 2004
Ryan Naraine |
Buffer Overflow Plugged in Sun ONE Web Server Sun releases service pack to fix denial-of-service vulnerability. |
BusinessWeek
May 24, 2004
Gene G. Marcial |
Sun's Eclipse Can't Last Forever Sun Microsystems has been an investment disaster for five years, with the stock way down. Most analysts are still quite negative on it. |
InternetNews
November 29, 2004
Michael Singer |
A Sun Ray in Every Home? Sun Microsystems is preparing a drive to put Sun Ray computers in more homes as part of its expanded desktop vision. |
Chemistry World
January 27, 2014
Phillip Broadwith |
US blocks imports from fourth Ranbaxy plant The US Food and Drug Administration has banned Indian drugmaker Ranbaxy from importing active pharmaceutical ingredients produced at its plant at Toansa, India, into the US. |
InternetNews
May 8, 2009
Andy Patrizio |
Sun Faces Suit Over Oracle Deal, Bribery Probe Three suits are filed to stop the Oracle takeover, while the company looks into possible overseas bribery incidents. |
JavaWorld
February 2001
Ashlee Vance |
Sun answers Microsoft with Net services push In a move that appears aimed squarely at Microsoft Corp.'s .Net Internet initiative, Sun Microsystems Inc. on Monday unveiled the Sun Open Net Environment (Sun ONE), which includes server software, development tools and other products for building Web-based e-commerce applications and services... |
Chemistry World
September 18, 2008
James Mitchell Crow |
Ranbaxy hit by US drug ban The US Food and Drug Administration (FDA) has banned the import of more than 30 drugs made by Ranbaxy, India's largest drugmaker. |
Knowledge@Wharton
October 8, 2003 |
Does Sun, Burned by Competition, Need a New Business Model? The clouds over Sun Microsystems are thickening as the company continues to struggle against competition from cheap, open systems offered by Dell, and from IBM and Hewlett-Packard in high-end business systems. |
InternetNews
April 5, 2004
Susan Kuchinskas |
Sun's Financial Strategy -- Can It Work? Sun and Microsoft's deal may not help hide Sun's perilous position in the marketplace. |
The Motley Fool
July 26, 2005
Melanie Hollands |
Sun Still Setting Sun's deal with StorageTek isn't the savior that the company and some investors may think. |
InternetNews
December 9, 2008
Paul Shread |
Sun's Financial Failings Greatly Exaggerated If you're expecting Sun Microsystems to be rescued by a white knight, you'll be disappointed: The company doesn't need to be saved. |
Pharmaceutical Executive
October 1, 2011
Amrita Ghaswalla |
Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied. |
InternetNews
September 14, 2009 |
Some Customers Are Sticking With Sun As HP and IBM aggressively pitch Sun customers, many are hanging in there. Oracle plans to debut a new Sun/Oracle database system this week. |
InternetNews
April 6, 2009
Andy Patrizio |
The Sun Doesn't Set Just Yet After reports say it spurned its suitor, IBM, what's ahead for Sun? |
InternetNews
October 20, 2008
Andy Patrizio |
Sun Preliminary Quarterly Figures Show a Drop While not final, they tend to be a fairly accurate indicator of where things will fall, and in this case, they are falling short. |
Pharmaceutical Executive
May 1, 2006
Joanna Breitstein |
Pharm Exec Q&A: Japanese Wedding Here, Daiichi Sankyo Pharma's John Alexander talks about the goals of its recent merger, the progress thus far, and shares insight into the development plans for its anti-platelet agent prasugrel. |
InternetNews
April 6, 2009
Paul Shread |
Sun Walks Away From IBM Merger Talks IBM's acquisition of Sun could have apparently fallen apart, at least for now. |
The Motley Fool
September 2, 2009
Eric Jhonsa |
Why Oracle's Getting More Than It Bargained For Sun's earnings show just how weak its hardware business is. |
InternetNews
October 6, 2005
David Needle |
Sun Plays Hardball With Server Promo Sun is targeting rivals Dell, IBM and Hewlett Packard in a series of aggressive marketing and sales programs. |
InternetNews
April 28, 2005 |
McNealy Mulls Taking Sun Private Sun's CEO and co-founder is considering a plan that would take his beloved Sun Microsystems off the market -- at least for a while. |
